Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's Disease.

Wong, Emily C L; Dulai, Parambir S; Marshall, John K; Jairath, Vipul; Reinisch, Walter; Narula, Neeraj

Wong, Emily C L; Dulai, Parambir S; Marshall, John K; Jairath, Vipul; Reinisch, Walter; Narula, Neeraj.

Afiliação

Wong ECL; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Dulai PS; Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Marshall JK; Division of Gastroenterology, Northwestern University, Chicago, IL, USA.
Jairath V; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Reinisch W; Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Narula N; Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.

Inflamm Bowel Dis ; 29(9): 1390-1398, 2023 09 01.

Article em En | MEDLINE | ID: mdl-36426810

Disease duration <5 years was independently associated with clinical remission at the end of induction. To reduce the placebo response rates in clinical trials, consideration should be given to stratification or exclusion of subjects by disease duration and mild disease severity as measured by objective biomarkers.

Assuntos

Doença de Crohn; Humanos; Doença de Crohn/tratamento farmacológico; Ustekinumab/uso terapêutico; Adalimumab/uso terapêutico; Proteína C-Reativa; Gravidade do Paciente; Indução de Remissão

Palavras-chave

Crohn's disease; inflammatory bowel disease; placebo; remission; response

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Crohn Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Inflamm Bowel Dis Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google